While established molecular MRD markers, such as NPM1 mutations and RUNX1::RUNX1T1, CBFB::MYH11, and PML::RARA fusions, are widely used in AML [16], there is currently no standardized or validated qPCR assay available for monitoring RUNX1::MECOM rearrangements [17], and thus, MRD tracking for this target was not pursued in our case. Here, CBFB is linked to acute myeloid leukemia.